Restructuring of dsm-firmenich Post-CVC Acquisition – as of end-May 2026

The strategic carving-out and structural re-engineering of dsm-firmenich’s Animal Nutrition & Health (ANH) division under private equity giant CVC Capital Partners represents one of the largest agri-business and life-sciences restructurings of 2026.

The €2.2 billion ($2.6 billion) deal marks the total realignment of a legacy business and a massive corporate restructuring that creates two distinct, standalone global entities for sharper and better focus.

Macro Strategic Mandate: Two Core Moves

For dsm-firmenich, the divestment is the final step in a multi-year strategy for a move away from volatile commodity cycles. Following its 2023 mega-merger (Royal DSM and Switzerland’s Firmenich) and the subsequent €1.5 billion sale of its Feed Enzymes business to Novonesis in 2025, this transaction completes the company’s transformation into a specialized consumer-facing player in Human Nutrition, Health, and Beauty.

While dsm-firmenich still retains a 20% minority equity stake to capture future upside, CVC holds operating control and has executed an immediate corporate restructuring of the €3.5 billion annualized revenue business.

Restructuring Plan – Dual-Company Approach

Rather than operating ANH as a singular integrated unit, CVC is splitting the asset into two distinct, standalone companies, both headquartered in the life-sciences hub of Kaiseraugst, Switzerland. This model isolates high-margin precision tech from capital-intensive, cyclical asset, manufacturing.

1. “Solutions Company”

This entity is designed as a high-margin, asset-light, customer-facing enterprise focused on digital precision farming and tailored nutritional blends.

• Core Portfolios: Includes Performance Solutions, Premixes and Precision Services.

• Strategic Growth Drivers: This entity will absorb advanced platforms like the Sustell Carbon Value Program (an ISO-assured carbon tracking system designed to measure and monetize farm-level emission reductions). It will leverage high-touch client data to sell bespoke premix formulations directly to massive commercial poultry, aquaculture, and livestock operations

2. “Essential Products Company”

Structured as a heavy-scale, vertically integrated global manufacturing powerhouse, built to weather macroeconomic supply-chain shocks.

• Core Portfolios: Houses Vitamins, Carotenoids and Aroma Ingredients.

• Strategic Position: It operates as an independent, high-volume supplier of core ingredients for animal feed, human food, and the global fragrance industry

• Interdependency: Crucially, dsm-firmenich and the Essential Products Company have entered into a long-term, structural supply agreement to guarantee vitamin sourcing across their human and animal nutrition value chains

Strategic Exclusions: To protect its long-term innovation pipeline, dsm-firmenich explicitly excluded its flagship methane-reducing feed additive Bovaer® and its sustainable algal omega-3 joint venture Veramaris™ from the sale. These high-growth assets remain fully under dsm-firmenich’s corporate umbrella.

Deal Structure & Financial Architecture

        [TOTAL REALIZED ANH VALUE: €3.7 BILLION]
                           |
      +--------------------+--------------------+
      |                                         |
[2025 CARVE-OUT]                       [2026 CVC DEAL]
Novonesis Feed Enzymes                  Enterprise Value: €2.2B
      (€1.5B)                           (Includes up to €0.5B Earn-out)
                                                |
                                        +-------+-------+
                                        |               |
                                    [CVC]     [dsm-firmenich]
                                   80% Equity      20% Equity

• Valuation Multiples: Factoring in the previous Novonesis carve-out, the total asset realization of the ANH division stands at €3.7 billion, implying an EV/Adjusted EBITDA multiple of approximately 10x based on its €3.5 billion revenue base

• Capital Allocation Strategy: * Upon closing, dsm-firmenich expects roughly €600 million in net cash proceeds

  • The board has immediately initiated a €500 million share buyback program to reduce issued capital and boost EPS.

  • Concurrently, dsm-firmenich has transitioned to a conservative, corporate-style dividend policy, aiming to maintain a stable floor of €2.50 per ordinary share with progressive increases over time.

  • The transaction resulted in a one-off, non-cash pre-tax impairment of €1.9 billion recorded on dsm-firmenich’s books to clear the path for clean consumer-product balance sheets.

Integration Outlook & Execution Risks

As the deal marches toward a projected close in late 2026, M&A advisors (led by White & Case, McKinsey, and EY on the buy-side, and EY-Parthenon on the sell-side) face complex operational hurdles.

1. Operational Re-structuring: Isolating thousands of global product SKUs across 8,000 employees into separate supply channels for the “Solutions” and “Essential Products” requires an incredibly complex IT, regulatory, and asset-carve-out execution

2. Global Antitrust Clearance: Given the market share held by the legacy ANH division in critical vitamin and carotenoid pathways, multi-jurisdictional anti-trust and regulatory reviews will be closely monitored by regulatory bodies in Europe, the US, and China through the end of the year